ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
Healthcare
$11.08 -0.14%
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
52W Low $6.27High $27.40
Volume 0.13M
Average 0.07M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$40.17M
FY 2025 · Annual
Net Income
-$39.72M
FY 2025 · Annual
Income Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 16.68K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 5.85M | 0 | 10.44M | 0 | 0 |
| Gross Profit | (5.84M) | 0 | (10.44M) | 0 | 0 |
| Gross Margin | -35031.9% | — | — | — | — |
| Research & Development | 4.95M | 16.09B | 7.88M | 10.64M | 33.38M |
| Selling, General & Admin | 3.31M | 7.29B | 6.38M | 6.19M | 6.79M |
| Operating Expenses | 4.63M | 23.38B | 8.45M | 16.83M | 40.17M |
| Depreciation & Amortization | 45.83K | 0 | 28.04K | 0 | 0 |
| EBITDA | (9.33M) | (17.78B) | (17.81M) | 2.86M | (39.72M) |
| EBITDA Margin | -55923.2% | — | — | — | — |
| Operating Income | (10.57M) | (23.38B) | (18.9M) | (16.83M) | (40.17M) |
| Operating Margin | -63350.5% | — | — | — | — |
| Interest Income | 4.73K | 0 | 0 | 0 | 0 |
| Interest Expense | 416.29K | 282.06M | 201.39K | 76.78K | 0 |
| Other Income / Expenses | (1.91M) | 5.32B | 1.39M | 19.61M | 448.16K |
| Income Before Tax | (12.48M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Pre-Tax Margin | -74804.2% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.98M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Net Margin | -71819.3% | — | — | — | — |
| EPS (Basic) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| EPS (Diluted) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| 231.42K | 300.1K | 491.71K | 1.04M | 1.76M | |
| 231.43K | 300.1K | 491.71K | 1.06M | 1.76M |
PMN Earnings Waterfall · TTM
NASDAQ:PMN · Revenue to Net Income
Key Ratios
EPS$-16.89
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$42.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-16.89, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
How much revenue does PMN generate?
ProMIS Neurosciences, Inc. (PMN) reported $0.00 of revenue in fiscal 2025.
Is PMN profitable?
ProMIS Neurosciences, Inc. (PMN) reported -$39.72M of net income.
Continue the stock analysis
Jump to another research area for this company.